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Abstract
Combined therapy with peritoneal dialysis (PD) and hemodialysis (HD) represents a treatment option for PD
patients who cannot maintain adequate solute and fluid removal. It has rapidly gained popularity in Japan,
and 15 years of accumulated experiences is available. Serum creatinine, serum β2 microglobulin (β2m), body
weight, and blood pressure decreased, whereas hemoglobin increased after initiating combined therapy.
These results indicated that both adequacy of dialysis and hydration status were significantly improved. In
addition, dialysate-to-plasma ratio of creatinine (D/P Cr) as obtained from peritoneal equilibration test (PET)
was decreased, probably due to the functional and histological improvements of the peritoneal membrane.
Combined therapy may have a good impact on the prevention of cardiovascular disease through reduction
of blood pressure, correction of fluid overload, and improvement of left ventricular hypertrophy. Quality of life
may improve as a result of decreases in uremic symptomatology and freedom from bag exchanges. On the
other hand, combined therapy with PD and HD has some concerns. A reduction in urine volume during
combined therapy indicates a decline in residual renal function, and may have potential negative impacts on
life expectancy. Furthermore, induction of combined therapy would increase the overall duration of PD treatment and
susceptibility to peritonitis. We have to pay attention to the development of encapsulating peritoneal sclerosis, as the
most serious complication of PD, because both prolonged PD duration and increased number of peritonitis episodes
are independent risk factors. Here, we propose criteria for the indication and discontinuation of combined therapy.
Under these criteria, Kt/V, serum β2m, and uremic symptoms including nutritional status, erythropoiesis-stimulating
agent-hyporesponsive anemia, and restless legs syndrome were used as markers of dialysis adequacy. On the other
hand, higher blood pressure, heart enlargement or pleural effusion on chest X-ray, and persistent peripheral edema
were used as markers of hydration status. Further studies, particularly prospective cohort studies with a large group of
cases, are needed to confirm the clinical efficacy of combined therapy with PD and HD.
Keywords: β2 microglobulin (β2m), Combined therapy, Dialysate-to-plasma ratio of creatinine (D/P Cr), Encapsulating
peritoneal sclerosis (EPS), Erythropoiesis-stimulating agent (ESA), Hemodialysis (HD), Peritoneal dialysis (PD), Quality of
life (QOL), Renal replacement therapy (RRT), Residual renal function (RRF)
Background
Peritoneal dialysis (PD) is recommended as a first-line
renal replacement therapy (RRT) for end-stage renal dis-
ease (ESRD) [1]. The main evidence to support this rec-
ommendation is that residual renal function (RRF) is
better preserved among patients treated with PD than in
those undergoing hemodialysis (HD) [2]. The degree of
RRF affects not only adequate solute and fluid removal,
but also patient survival [3, 4]. However, standard PD
is not always sufficient to avoid both the risk of
uremic complications of inadequate dialysis and fluid
overload, especially once loss of RRF has occurred.
Peritoneal permeability is also widely recognized as
showing gradual enhancement over time on PD ther-
apy. In Japanese PD patients, the 5-year technique sur-
vival rate was estimated as 70 %, and the most
common reasons for technique failure are inadequate
dialysis and/or ultrafiltration failure [5]. Treatment
options for these patients include switching to HD or
starting combined therapy with PD and HD, generally
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week.
Combined therapy with PD and HD was introduced
in Japan in the 1990s, and the first report was written
by Watanabe and Kimura [abstract: Watanabe S and
Kimura Y et al. Nihon Touseki Igakukai Zasshi. 1993;26
(suppl 1):911]. Kawanishi et al. [6] published the first
report in English in 1999, describing 12 patients treated
with combined therapy. A PD + HD combination ther-
apy study group was set up in 1996, had met annually
and discussed details of the application, mode, and in-
dication of this combination therapy, and issued the
first clinical recommendation in 2004 [7]. Since then,
combined therapy has rapidly gained popularity in
Japan, and as of 2012, approximately 1800 patients
(20 % of all PD patients) were estimated to be receiving
this therapy [8].
Although several reports have shown the effectiveness
and impact of combined therapy with PD and HD, most
have been limited by sample size or by being single-center
studies [6, 9–20] (Table 1). In these reports, the termin-
ology have not been standardized (i.e., combined therapy,
combination therapy, hybrid therapy, complementary dia-
lysis, and bimodal dialysis). We recently reported clinical
outcomes for more than 100 patients treated with com-
bination therapy across nine centers in Japan [21]. Ac-
cording to that study, the PD duration prior to switching
to combined therapy was approximately 2–4 years and the
reason for switching was inadequate dialysis in 25–83 %
and fluid overload in 16–42 % (Table 1).
This review summarizes the experience with combined
therapy using previous reports, and considers the clinicalTable 1 List of previous reports regarding combined therapy with P
Author, year Study design n Duration of P
combined the
Kawanishi, 1999 [6] Single center retrospective 12 4.1 ± 3.6
Hashimoto, 2000 [9] Single center retrospective 6 2.1 ± 0.9
Kawanishi, 2002 [10] Single center retrospective 31
Kanno, 2003 [11] Single center retrospective 7 4.3 ± 1.1
Agarwal, 2003 [12] Multicenter retrospective 31 4.3 ± 4.1
McIntyre, 2004 [13] Prospective 8 0
Kawanishi, 2006 [14] Multicenter retrospective 52 3.6 ± 3.0
Hoshi, 2006 [15] Single center retrospective 9 3.6 ± 0.2
Kawanishi, 2007 [16] Single center retrospective 23 2.3 ± 1.7
Moriishi, 2010 [17] Single center retrospective 76
Matsuo, 2010 [18] Single center retrospective 53 4.1 ± 3.2
Tanaka, 2011 [19] Single center retrospective 14 3.8 (mean)
Suzuki, 2012 [20] Single center retrospective 26
Maruyama, 2014 [21] Multicenter retrospective 104 4.0 ± 3.5
PD peritoneal dialysis, HD hemodialysisefficacy of this therapy. We also propose criteria for both
initiation and discontinuation of combined therapy.
Criteria for initiation of combined therapy
For the better management of PD, adequate solute and
fluid removal are essential and targets have been defined in
several guidelines, including the Kidney Disease Outcomes
Quality Initiative (KDOQI) guideline [22], the International
Society for Peritoneal Dialysis (ISPD) guideline [23], and
the Japanese Society for Dialysis Therapy (JSDT) guideline
[24]. Weekly Kt/V is widely used to assess solute removal,
and is determined using the combined renal and peritoneal
clearance of urea. The guidelines recommend maintaining
weekly Kt/V >1.7. In addition, persistent anorexia, deterior-
ation of nutritional status, erythropoiesis-stimulating agent
(ESA)-hyporesponsive anemia, and restless legs syndrome
could reflect inadequate dialysis even if the target for solute
clearance is achieved. Maintenance of euvolemia is also im-
portant for the better management of PD patients. Reduc-
tion in both ultrafiltration (UF) volume and urinary volume
induce volume overload. The presence of peripheral edema,
higher or drug-resistant blood pressure, and heart enlarge-
ment or pleural effusion on chest X-rays could be signs of
fluid overload. Although definitive criteria for the initiation
of combined therapy have yet to be established, patients
who cannot maintain adequate solute removal and fluid re-
moval are candidates for this therapy.
Table 2 summarizes the clinical and biochemical pa-
rameters at the start of combined therapy with PD and
HD. Creatinine levels were elevated (12.0–13.5 mg/dL)
and urine volume was decreased (150–250 mL/day),
whereas weekly Kt/V was maintained at a target levelD and HD
D at start of
rapy (years)
Reason for combined therapy








Table 2 Clinical and biochemical parameters at the start of combined therapy with PD and HD
Author, year SBP [mmHg] DBP [mmHg] Urine volume [mL/day] UF volume [mL/day] BUN [mg/dL] Cr [mg/dL] β2m [mg/L] D/P Cr Weekly Kt/V Weekly Ccr [L/week/1.73 m2]
Hashimoto, 2000 [9] 1.98 ± 0.28 58.6 ± 10.5
Agarwal, 2003 [12] 1.96 ± 0.51
Kawanishi, 2006 [14] 152 ± 25 151 ± 25 794 ± 447 63.0 ± 18.2 13.1 ± 3.3 35.8 ± 14.3 1.86 ± 0.52
Hoshi, 2006 [15] 141 ± 5 72 ± 4 76.4 ± 7.8 13.5 ± 0.8
Kawanishi, 2007 [16] 33.3 ± 11.3 1.55 ± 0.4 42.0 ± 7.7
Matsuo, 2010 [18] 145 ± 22 84 ± 17 253 ± 405 907 ± 579 61 ± 16 13.5 ± 3.6 35.9 ± 7.5 0.65 ± 0.11 50.2 ± 5.3
Tanaka, 2011 [19] 156 ± 17 200 (0–900) 12.2 ± 2.8 2.2 ± 0.4
Maruyama, 2014 [21] 144 ± 22 80 ± 14 150 (0–2000) 1000 (−500–2350) 59.2 ± 14.6 12.9 ± 3.4 34.4 ± 7.2 0.67 ± 0.11 1.8 ± 0.4 49.9 ± 13.1
PD peritoneal dialysis, HD hemodialysis, SBP systolic blood pressure, DBP diastolic blood pressure, UF ultrafiltration, BUN blood urea nitrogen, Cr creatinine, β2m β2 microglobulin, D/P Cr dialysate-to-plasma ratio of
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suggest that small solute removal was maintained in
many cases, and fluid overload was a considerable rea-
son for the initiation of combined therapy. Indeed, sys-
tolic blood pressure was elevated (140–156 mmHg)
despite the high UF volume (800–1000 mL/day).
Although the removal of urea nitrogen or creatinine
was relatively maintained, β2 microglobulin (β2m) levels
were elevated (33–36 mg/L). The level of serum β2m, as
a middle-molecule uremic toxin, is known to influence
the mortality of HD patients, and is now recognized as a
potential guide to the adequacy of dialysis in this popu-
lation [25]. Since a higher β2m level represented an in-
dependent risk factor for encapsulating peritoneal
sclerosis (EPS), the most serious complication of PD
[26], β2m level is expected to be a prognostic factor for
both PD alone and for combined therapy.
Two reports showed dialysate-to-plasma ratio of
creatinine (D/P Cr), obtained from a peritoneal equili-
bration test (PET), at the start of combined therapy
[18, 21]. Increased D/P Cr reflects deterioration in
peritoneal function, and increases gradually with dur-
ation of PD and cumulative glucose exposure [27]. In
addition, D/P Cr is one of the important risk factors
for EPS [28]. Since D/P Cr was not elevated, peritoneal
deterioration was not clinically evident at the start of
combined therapy.
PD patients who cannot maintain adequate solute re-
moval and fluid removal are candidates for combined ther-
apy as described before, and we proposed for criteria for
the initiation of combined therapy with PD and HD
(Table 3). In these criteria, patients with limited peritonealTable 3 Proposed indications for combined therapy with PD
and HD
1. Insufficient solute removal (inadequate dialysis)
Total Kt/V <1.7
β2 microglobulin >30 mg/L
Other uremic symptoms




2. Insufficient fluid removal (fluid overload)
Higher or drug-resistant blood pressure
Heart enlargement or pleural effusion on chest X-rays
Persistent peripheral edema, anasarca
3. Other indications
Limited peritoneal capacity
Cardiovascular instability in HD
PD peritoneal dialysis, HD hemodialysis, BMI body mass index, SGA subjective
global assessment, ESA erythropoiesis-stimulating agentcapacity and presenting with cardiovascular instability in
HD were also candidates for combined therapy even if both
solute and fluid removal were maintained [29].
Changes in clinical and biochemical parameters after
initiating combined therapy
Table 4 summarizes changes in clinical and biochemical
parameters after the initiation of combined therapy. Ac-
cording to these comparative analyses, body weight and
blood pressure decreased and hemoglobin increased,
and serum creatinine levels decreased despite the de-
creased urine volume [14, 15, 18, 19, 21]. These results
indicated that both the adequacy of dialysis and hydra-
tion status were significantly improved. Several studies
have demonstrated that hemoglobin levels increased
with a reduction in ESA dose, indicated that the eleva-
tion in hemoglobin level was due to corrections of both
fluid overload and ESA hyporesponsiveness one of the
uremic symptoms [15, 18, 19].
Changes in serum β2m varied between reports
[16, 18, 21]. Dialysis clearance of β2m with HD using a
high-flux membrane is well known to be much higher
than with PD [30, 31]. Unlike in PD, serum β2m in pa-
tients receiving HD changes dramatically over a week, and
we usually measure the highest value at the start of an HD
session. Since β2m represents a useful risk factor in PD
patients, as previously mentioned, the decline under com-
bined therapy is thought to be a beneficial effect [26].
In most studies, D/P Cr decreased after switching to
combined therapy [16, 18, 21]. Several possible explana-
tions for this have been suggested. Firstly, combined
therapy could limit further deterioration of the periton-
eal membrane by decreasing exposure to glucose and
elimination of uremic toxins. In addition to cumulative
glucose exposure [32], uremia per se [33] is also associ-
ated with structural alternations in the peritoneal mem-
brane. Secondly, peritoneal rest could have a positive
impact on peritoneal function. In general, PD was not
carried out on the day of a HD session, and almost half
of the patients did not undergo PD on another day, de-
fined as a “PD holiday”. Several in vivo [34] and in vitro
[35] studies have shown that peritoneal rest reduces the
alteration of the mesothelial cells and improves periton-
eal function. Thirdly, histological improvement of peri-
toneal edema secondary to improvement of fluid status
might lead to reduction in D/P Cr [36].
Assessment of efficiency of combined therapy
Although small solute removal was obviously improved
after switching from PD alone to combined therapy, no
standard method has been devised to calculate solute clear-
ances in combined therapy. Kawanishi et al. [14, 16, 29]
used equivalent renal clearance (EKR) of urea as proposed
by Casino et al. [37], and both total Kt/V and total weekly
Table 4 Changes in clinical and biochemical parameters
Author, year Follow-up BW BP Urine volume Cr β2m Hb D/P Cr
Kanno, 2003 [11] 3 months Decreased
Kawanishi, 2006 [14] 24 months Decreased Decreased Decreased Decreased Unchanged
Hoshi, 2006 [15] 36 months Decreased Unchanged Increased
Kawanishi, 2007 [16] 6 months Decreased Unchanged or decreased
Matsuo, 2010 [18] 12 months Decreased Decreased Decreased Decreased Decreased Increased Decreased
Tanaka, 2011 [19] 9 months Decreased Decreased Unchanged Decreased Increased
Maruyama, 2014 [21] 3 months Decreased Unchanged Decreased Decreased Unchanged Increased Decreased
BW body weight, BP blood pressure, Cr creatinine, β2m β2 microglobulin, Hb hemoglobin, D/P Cr dialysate-to-plasma ratio of creatinine
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starting combined therapy. The JSDT guideline [24] recom-
mends that the adequacy of dialysis should be determined
using the concept of body fluid clear space in combined
therapy [24, 31].
Combined therapy and cardiovascular disease
Cardiovascular disease is one of the most serious com-
plications in dialysis patients, and is responsible for
33.5 % of deaths among Japanese dialysis patients [8].
Since both inadequate dialysis and fluid overload are risk
factors, initiating combined therapy may have a positive
impact. Although no reports have clarified the effect of
combined therapy on the incidence of cardiovascular
disease, changes in surrogate markers have been re-
ported. Tanaka et al. [19] found that left ventricular mass
index (LVMI) on echocardiography, a well-known risk
factor for atherosclerosis, was significantly reduced at
9 months after switching therapy. They also reported
that systolic blood pressure was significantly decreased
despite prescription of the same dose of antihypertensive
medication. Hypertension is a risk factor for mortality,
and control of blood pressure by antihypertensive medi-
cation reduced cardiovascular morbidity and mortality
rates in HD [38]. Several other reports have indicated
the corrective action on blood pressure, with a reduction
in number of antihypertensive drugs [15, 18]. Interest-
ingly, Matsuo et al. [39] recently reported that the cu-
mulative hazard ratio for death was not lower for
combined therapy than for HD or PD alone. These re-
sults suggest that switching from PD alone to combined
therapy may have a good clinical impact on the preven-
tion of cardiovascular disease.
Combined therapy and quality of life
Along with reducing mortality and morbidity, maintain-
ing high quality of life (QOL) is also important for the
management of dialysis patients. A meta-analysis by
Wyld et al. [40] reported that PD resulted in a clinically
higher QOL than HD, however, but the difference was
not statistically significant. Hashimoto et al. [9] found
that QOL was improved among six patients switchingfrom PD alone to combined therapy. They concluded
that the improvements in QOL may have resulted from
decreases in uremic symptomatology and freedom from
bag exchanges.
Criteria for discontinuation of combined therapy and
prevention of EPS
Combined therapy with PD and HD has some concerns.
Urine volume decreases during combined therapy. Since
many reports have shown an association between lower
RRF and higher mortality among PD patients [3, 4], a
decline in RRF by combined therapy might require at-
tention. Further study will be needed to clarify the asso-
ciation between renal volume and outcome among
patients receiving combined therapy. Furthermore, in-
duction of combined therapy would increase the overall
duration of PD treatment and susceptibility to periton-
itis. Both prolonged PD duration and increased number
of peritonitis episodes are well known as independent
risk factors for EPS [28], and Yamamoto et al. [41] re-
ported that the cut-off points for these parameters are
115.2 months and two times, respectively.
In addition to the absence of criteria for initiation, criteria
for discontinuation of combined therapy have also not yet
been established. For those patients receiving combined
therapy who cannot maintain adequate solute removal and
fluid removal, we have to consider discontinuation of com-
bined therapy and switching to other mode of RRT, espe-
cially HD thrice weekly. We also proposed criteria for
discontinuation of combined therapy PD and HD (Table 5),
determined based on the criteria for conventional PD and
consideration of the prevention of EPS development as well
as impaired solute and fluid removal was an important
issue [24]. It is to be noted that conventional solution was
used in the most of previous studies. It is well known that
neutral-pH, low-glucose degradation products solutions po-
tentially influence the integrity of the peritoneal membrane
[42]. Indeed, Yohanna et al. found that the use of these new
solutions resulted in better preservation of RRF and greater
urine volumes in systematic review [43]. In the future, the
reconsideration of criteria for discontinuation will be
needed.
Table 5 Proposal for discontinuation of combined therapy with
PD and HD
1. Insufficient solute removal (inadequate dialysis)
β2 microglobulin >35 mg/L
Other uremic symptoms




2. Insufficient fluid removal (fluid overload)
Higher or drug-resistant blood pressure
Heart enlargement or pleural effusion on chest X-rays
Persistent peripheral edema, anasarca




PD peritoneal dialysis, HD hemodialysis, SGA subjective global assessment, ESA
erythropoiesis-stimulating agent, EPS encapsulating peritoneal sclerosis, D/P Cr
dialysate-to-plasma ratio of creatinine
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Most reports of combined therapy were from Japan, and
limited experiences have been reported from the USA
[12] and UK [13]. Agarwal et al. [12] observed an im-
provement in the clinical symptoms for which combined
therapy was initiated in 31 patients. McIntyre et al. [13]
conducted a prospective study of combined therapy, re-
ferred to as bimodal dialysis, in eight incident patients
reaching ESRD, and found that RRF was controlled and
both blood pressure and LVMI were reduced.
Conclusions
According to the previous reports, both inadequate dia-
lysis and fluid overload were significantly improved by
switching from PD alone to combined therapy with PD
and HD. In addition, combined therapy has potential ef-
fects on improved QOL and correction of peritoneal de-
terioration. However, the clinical outcomes including
mortality, morbidity, and the incidence of EPS remain
unknown. Furthermore, criteria for both initiation and
discontinuation of combined therapy have not been
established. To solve these clinical questions, we are
now undertaking a prospective cohort study.
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